Newly diagnosed ALL: testing a treatment after Hyper-CVAD
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Philadelphia-negative B- or T-cell ALL confirmed by lab testing, with more than 10% leukemia cells in blood or bone marrow at diagnosis
- You finished Hyper-CVAD arm 1A and fully recovered from it before starting this trial
- You can follow the study schedule and give informed consent (or assent, if applicable)
- Your energy level is fairly good (ECOG 0 to 1) and your heart function is strong (ejection fraction at least 50%)
- Your liver and kidney tests are within allowed ranges (bilirubin/creatinine under 1.5 times normal; AST/ALT under 3 times normal)
- If you can become pregnant (or can father children), you must use strict non-hormonal contraception and have a negative pregnancy test; you also cannot donate sperm during the study and for 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial studies a specific treatment plan (“CAV regimen”) for people with B-cell ALL that has either come back or did not respond to standard treatment. It may help control the leukemia, if you meet the health and safety requirements.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This trial tests a treatment plan for adults with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see how well the treatment works and to manage the disease, with some patients also receiving a stem cell transplant.
This trial tests a combination of a targeted drug and low-dose chemotherapy for adults newly diagnosed with a certain type of acute lymphoblastic leukemia (ALL). The goal is to find a gentler but effective treatment that may be easier for patients to tolerate.
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.